Semaglutide Compounding Dispute: Novo Nordisk Heads To Court

Original Article by Tamar Kahn | Business Day | 2 June 2026

The Semaglutide Compounding Dispute intensifies as Novo Nordisk takes iDexis to court over illegal manufacturing of weight-loss injections.

The Semaglutide Compounding Dispute intensifies as Novo Nordisk takes iDexis to court over illegal manufacturing of weight-loss injections.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here